Skip to main content

Drug Interactions between maralixibat and rosuvastatin

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

rosuvastatin maralixibat

Applies to: rosuvastatin and maralixibat

MONITOR: Coadministration with maralixibat may decrease the plasma concentrations of drugs that are substrates of organic anion transporting polypeptide 2B1 (OATP2B1), such as statin drugs. Maralixibat is an inhibitor of the OATP2B1 transporter in vitro. A decrease in the oral absorption of drugs that rely on OATP2B1-mediated uptake in the gastrointestinal tract may occur when administered with maralixibat. In clinical studies, coadministration of maralixibat (4.75 mg once daily in the morning) with daily evening doses of simvastatin, lovastatin, or atorvastatin did not result in clinically relevant effects on the pharmacokinetics of these statin drugs or their metabolites. However, the effect of maralixibat on the pharmacokinetics of OATP2B1substrate drugs at higher daily doses, such as the maximum recommended daily dose of 28.5 mg (for body weight of 70 kg or more), has not been evaluated in clinical studies.

MANAGEMENT: Until more information is available, caution is advised if maralixibat is used concomitantly with drugs that are substrates of OATP2B1. Dosage adjustments as well as clinical and laboratory monitoring of OATP2B1 substrate drugs may be appropriate whenever maralixibat is added to or withdrawn from therapy.

References

  1. (2021) "Product Information. Livmarli (maralixibat)." Mirum Pharmaceuticals, Inc.

Switch to consumer interaction data

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer